Healthcare / Diagnostics & ResearchKOSDAQ
$1910.00
-53.00 (-2.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $5.2B · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$55.2B
P/E
11.8x
↓EV/EBITDA
6.7x
↓ROE
5.8%
↑Gross Margin
47.0%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.3%
FCF CAGR
-5.6%
FCF margin
22.7%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.78B · net income $4.69B · FCF $5.18B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.78B | $22.78B | $17.85B | $14.84B | $17.96B |
| Net Income | $4.69B | $4.69B | $5.82B | $4.81B | $7.13B |
| EBITDA | $7.86B | $7.86B | $8.67B | $7.12B | $9.68B |
| EPS | 162.00 | 162.00 | 200.00 | 160.00 | 239.00 |
| Gross Margin | 47.0% | 47.0% | 47.5% | 48.5% | 61.9% |
| Operating Margin | 17.3% | 17.3% | 14.5% | 9.3% | 31.4% |
| Net Margin | 20.6% | 20.6% | 32.6% | 32.4% | 39.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 8.38 | 8.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $5.18B | $5.18B | $8.41B | $3.99B | $6.15B |
| Returns | |||||
| ROE | 5.8% | 5.8% | 7.6% | 6.5% | 10.1% |
| Valuation | |||||
| P/E | 11.79 | 11.79 | 10.95 | 16.06 | 12.87 |
| EV/EBITDA | 6.66 | 6.66 | 6.66 | 9.57 | 9.03 |
| P/B | 0.68 | 0.68 | 0.83 | 1.04 | 1.30 |
| Growth & Yield | |||||
| Revenue Growth | 27.7% | 27.7% | 20.2% | -17.3% | — |
| EPS Growth | -19.0% | -19.0% | 25.0% | -33.1% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.5%
EPS terminal req.
$169.48
Spread vs growth
-20.5%
5Y implied EPS CAGR
4.8%
EPS terminal req.
$205.07
Spread vs growth
-23.8%
10Y implied EPS CAGR
7.4%
EPS terminal req.
$330.27
Spread vs growth
-26.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.5%
Start / end P/E
14.7x → 11.8x
EPS bridge
200.00 → 162.00
Residual
+3.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.